Thyroid Langerhans cell histiocytosis concurrent with papillary thyroid carcinoma: A case report and literature review

Bin Mi, Di Wu, Yue Fan, Benjamin Ka Seng Thong, Yudong Chen, Xue Wang, Chaofu WangFrontiers in Medicine 2023 · DOI

Abstract

Langerhans cell histiocytosis (LCH) is a rare clonal neoplasm of myeloid dendritic cells that seldom involves the thyroid gland. This report details a unique case of a 34-year-old woman presenting with concurrent papillary thyroid carcinoma (PTC) and LCH, including LCH metastasis to cervical lymph nodes. Despite shared morphological features, molecular analysis revealed a BRAF V600E mutation only in the PTC lesion, suggesting independent pathogenic origins for the two neoplasms. This case highlights the diagnostic challenges and the potential role of chronic inflammation in the development of thyroid LCH.

Introduction

Papillary thyroid carcinoma (PTC) is the most prevalent thyroid malignancy, whereas LCH involvement of the thyroid is exceptionally rare. The co-occurrence of these two distinct pathologies presents a significant diagnostic hurdle for clinicians and pathologists alike. Both LCH and PTC cells can display "nuclear grooves," a feature that often leads to the misidentification of LCH during routine fine-needle aspiration cytology (FNAC) when PTC is also present. In fact, literature suggests that LCH is correctly identified pre-operatively in less than 30% of concurrent cases.

Clinical Presentation and Diagnostic Methods

A 34-year-old Chinese woman was found to have thyroid nodules and cervical lymph node enlargement during a routine physical examination. The clinical team employed a multi-modal diagnostic approach to characterize the lesions:

  • Imaging: Neck ultrasonography identified suspicious nodules in the thyroid.
  • Cytology: FNAC initially suggested PTC accompanied by Hashimoto's thyroiditis (HT).
  • Histopathology: Post-operative examination of the resected thyroid and lymph nodes revealed the presence of both classical PTC and LCH.
  • Immunohistochemistry (IHC): LCH was definitively confirmed using markers such as CD1a, Langerin, and S-100. PTC was confirmed via AE1/AE3, TTF-1, and CK19.
  • Molecular Testing: PCR-based testing was conducted for BRAF V600E, TERT promoter, and HRAS mutations.
Neck ultrasound showing thyroid nodules (A: PTC, B: LCH)

Key Insights and Discussion

Morphological Mimicry

The primary diagnostic challenge is the morphological similarity between LCH and PTC cells. While LCH cells typically possess more granular cytoplasm and lack the "ground-glass" nuclei characteristic of PTC, the presence of nuclear grooves in both can be misleading. IHC is essential to distinguish neoplastic LCH from reactive Langerhans cell hyperplasia, with cyclin D1 and p53 serving as helpful adjunct markers.

The patient in this case also presented with Hashimoto’s thyroiditis. The authors hypothesize that the chronic inflammatory environment of HT, characterized by elevated cytokines like IFN-γ, may create a niche that triggers the clonal expansion of Langerhans cells, potentially leading to the development of LCH.

Molecular Independence

Molecular profiling revealed that the PTC carried the BRAF V600E mutation, while the LCH metastatic lesions did not. This suggests that, in this specific instance, the two neoplasms likely arose through independent genetic events rather than from a shared early progenitor cell. This finding contrasts with some other reported cases where BRAF mutations were found in both pathologies.

A review of 22 previously published cases of concurrent thyroid LCH and PTC (dating back to 1991) revealed several key trends:

  • Demographics: Unlike general LCH, which is more common in children, concurrent thyroid LCH and PTC typically occurs in adults (median age 37).
  • Gender: There is a slight male predominance (59.1% of cases).
  • Prognosis: Most patients remain stable following surgical intervention, though long-term data is limited due to the rarity of the condition.

Conclusion

Accurate diagnosis of concurrent thyroid LCH and PTC requires high clinical suspicion and rigorous IHC confirmation. Because thyroid LCH may be a harbinger of multisystem disease involving the lungs or pituitary gland, the authors recommend comprehensive systemic screening (such as PET/CT or bone scans) and extended follow-up for these patients. The patient in this report remains in stable condition three months post-surgery.

Summary updated

Abstract

Langerhans cell histiocytosis (LCH) is a clonal neoplasm of myeloid dendritic cells, rarely involving the thyroid gland. Papillary thyroid carcinoma (PTC) is the most common histological subtype of thyroid cancer. We report a rare case of a 34-year-old Chinese woman who has LCH with PTC and cervical lymph node metastasis of LCH, with a review of the literature. The patient has thyroid nodules and cervical lymph node enlargement detected by neck ultrasound during physical examination. Fine needle aspiration cytology (FNAC) showed PTC with Hashimoto's thyroiditis and <i>BRAF V600E</i> mutation after thyroidectomy and lymph node dissection. Histopathological examination suggests that LCH was concurrent with classical PTC, accompanied by LCH cervical lymph node metastasis. No <i>BRAF, HRAS</i>, and <i>TERT</i> promoter mutations were detected in LCH metastatic lesions. The patient is in stable clinical condition currently.
BibTeX
@inproceedings{mi2023thyroid,
  author = {Bin Mi and Di Wu and Yue Fan and Benjamin Ka Seng Thong and Yudong Chen and Xue Wang and Chaofu Wang},
  title = {{Thyroid Langerhans cell histiocytosis concurrent with papillary thyroid carcinoma: A case report and literature review}},
  booktitle = {Frontiers in Medicine},
  year = {2023},
  doi = {10.3389/fmed.2022.1105152},
}
Figure